Kuangli Bio-Tech Holdings Co., Ltd. (TPE:6431)

Revenue by Segment

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Biotechnology Segment	335.13M	351.22M	277.02M	342.16M	332.63M
Biotechnology Segment Growth	-4.58%	26.79%	-19.04%	2.86%	-
Health Management Department	41.90M	30.09M	16.36M	-	-
Health Management Department Growth	39.28%	83.92%	-	-	-
Total	377.03M	381.30M	293.37M	342.16M	332.63M
Total Growth	-1.12%	29.97%	-14.26%	2.86%	282.47%

Revenue by Geography

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
China	335.13M	351.22M	277.02M	342.16M	332.63M
China Growth	-4.58%	26.79%	-19.04%	2.86%	282.47%
Taiwan	41.90M	30.09M	16.36M	-	-
Taiwan Growth	39.28%	83.92%	-	-	-
Total	377.03M	381.30M	293.37M	342.16M	332.63M
Total Growth	-1.12%	29.97%	-14.26%	2.86%	282.47%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 18, 2026

Data Sources Report a data error